We are live on !
Find out more
SFAM
Springhill Fund Asset Management Portfolio holdings
AUM
$20.9M
Turnover
80%
This Fund
S&P 500
This Quarter Est. Return
+8.77%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$20.9M
AUM Growth
-$40.7M
(-66%)
Cap. Flow
-$44.1M
Cap. Flow % of AUM
Cap. Flow %
-211.32%
Top 10 Holdings %
Top 10 Hldgs %
82.88%
Holding
30
New
13
Increased
2
Reduced
4
Closed
11
Avg Time Held
0.1
years
Top 10 Avg Time Held
0.1
years
Top 20 Avg Time Held
0.1
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Summit Therapeutics
SMMT
|
+$2.49M |
| 2 |
Janux Therapeutics
JANX
|
+$1.84M |
| 3 |
Regeneron Pharmaceuticals
REGN
|
+$1.79M |
| 4 |
Neurocrine Biosciences
NBIX
|
+$1.72M |
| 5 |
Jazz Pharmaceuticals
JAZZ
|
+$1.29M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Legend Biotech
LEGN
|
+$6.21M |
| 2 |
Cytokinetics
CYTK
|
+$6.15M |
| 3 |
Akero Therapeutics
AKRO
|
+$5.56M |
| 4 |
AstraZeneca
AZN
|
+$5.01M |
| 5 |
Vera Therapeutics
VERA
|
+$4.63M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
VRNA
1
DELISTED
Verona Pharma
VRNA
| $4.03M | 19.32% |
63,499
-71,953
| -53% | -$4.3M |
2024 Q4
1 quarter
|
|
|
2
Summit Therapeutics
SMMT
$11.8B
| $2.4M | 11.49% |
+124,307
| New | +$2.49M |
2025 Q1
0 quarters
|
|
|
3
Janux Therapeutics
JANX
$1.07B
| $2.12M | 10.16% |
78,500
+48,900
| +165% | +$1.84M |
2024 Q4
1 quarter
|
|
|
4
Regeneron Pharmaceuticals
REGN
$99.4B
| $1.65M | 7.9% |
+2,600
| New | +$1.79M |
2025 Q1
0 quarters
|
|
|
5
Neurocrine Biosciences
NBIX
$14.8B
| $1.51M | 7.21% |
+13,612
| New | +$1.72M |
2025 Q1
0 quarters
|
|
6
Insmed
INSM
$24B
| $1.46M | 7.02% |
19,192
-50,308
| -72% | -$3.85M |
2024 Q4
1 quarter
|
|
7
DELISTED
Soleno Therapeutics
SLNO
| $1.42M | 6.8% |
19,858
+18,065
| +1,008% | +$880K |
2024 Q4
1 quarter
|
|
|
8
Jazz Pharmaceuticals
JAZZ
$13.9B
| $1.22M | 5.86% |
+9,853
| New | +$1.29M |
2025 Q1
0 quarters
|
|
|
9
DELISTED
Akero Therapeutics
AKRO
| $807K | 3.87% |
19,925
-131,275
| -87% | -$5.56M |
2024 Q4
1 quarter
|
|
10
argenx
ARGX
$55B
| $678K | 3.25% |
+1,146
| New | +$723K |
2025 Q1
0 quarters
|
|
11
Eli Lilly
LLY
$1.26T
| $674K | 3.23% |
+816
| New | +$679K |
2025 Q1
0 quarters
|
|
12
Protagonist Therapeutics
PTGX
$9.02B
| $622K | 2.98% |
+12,859
| New | +$539K |
2025 Q1
0 quarters
|
|
13
TG Therapeutics
TGTX
$9.18B
| $532K | 2.55% |
+13,500
| New | +$454K |
2025 Q1
0 quarters
|
|
14
Tarsus Pharmaceuticals
TARS
$3.43B
| $363K | 1.74% |
+7,076
| New | +$350K |
2025 Q1
0 quarters
|
|
15
Ascendis Pharma A/S
ASND
$16.4B
| $339K | 1.62% |
+2,173
| New | +$310K |
2025 Q1
0 quarters
|
|
16
Rhythm Pharmaceuticals
RYTM
$6.43B
| $332K | 1.59% |
+6,277
| New | +$348K |
2025 Q1
0 quarters
|
|
17
BioNTech
BNTX
$22B
| $273K | 1.31% |
+3,000
| New | +$336K |
2025 Q1
0 quarters
|
|
18
DELISTED
SpringWorks Therapeutics
SWTX
| $260K | 1.25% |
+5,897
| New | +$271K |
2025 Q1
0 quarters
|
|
19
Cogent Biosciences
COGT
$5.16B
| $177K | 0.85% |
29,491
-519,063
| -95% | -$4.07M |
2024 Q4
1 quarter
|
|
20
Abivax
ABVX
$7.43B
| – | – |
-207,600
| Closed | -$1.52M | – |
|
|
21
AstraZeneca
AZN
$289B
| – | – |
-38,250
| Closed | -$5.01M | – |
|
22
Bicycle Therapeutics
BCYC
$254M
| – | – |
-116,400
| Closed | -$1.63M | – |
|
23
Cullinan Oncology
CGEM
$961M
| – | – |
-276,400
| Closed | -$3.37M | – |
|
|
24
Cytokinetics
CYTK
$8.62B
| – | – |
-130,735
| Closed | -$6.15M | – |
|
25
Bright Minds Biosciences
DRUG
$258M
| – | – |
-60,648
| Closed | -$2.18M | – |
|
Similar funds
Springhill Fund Asset Management's Q1 2025 Portfolio in Review
As of Q1 2025, Springhill Fund Asset Management held 30 positions worth $20.9M, down 66% from $61.6M the previous quarter. Its ten largest holdings account for 83% of the portfolio.
Springhill Fund Asset Management withdrew a net $44.1M in Q1 2025, closing 11 positions and reducing 4 holdings. Its most notable exit was Legend Biotech, an estimated $6.21M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
Against the trend, Springhill Fund Asset Management opened a new position in Summit Therapeutics worth $2.4M.
- Springhill Fund Asset Management's largest Q1 2025 buy was Summit Therapeutics: 124,307 shares worth $2.4M.
- Springhill Fund Asset Management added most to Janux Therapeutics in Q1 2025, an estimated $1.84M increase.
- Springhill Fund Asset Management's biggest Q1 2025 reduction was Akero Therapeutics, cutting an estimated $5.56M.
- Springhill Fund Asset Management fully exited Legend Biotech in Q1 2025, selling an estimated $6.21M.
- Springhill Fund Asset Management's ten largest holdings make up 83% of its $20.9M portfolio in Q1 2025.
- Springhill Fund Asset Management opened 13 new positions and closed 11 in Q1 2025.
- Springhill Fund Asset Management's portfolio value fell 66% quarter-over-quarter to $20.9M.
Based on Springhill Fund Asset Management's 13F filing for Q1 2025, filed 14 May 2025.